Pulmonary hypertension encompasses a range of conditions directly or indirectly leading to
elevated pressures within the pulmonary arteries. Five main groups of pulmonary …

Pulmonary arterial hypertension (PAH) is a devastating disease that involves pulmonary
vasoconstriction, small vessel obliteration, large vessel thickening and obstruction, and …

The initiation and development of major inflammatory diseases, ie, cancer, vascular
inflammation, and some autoimmune diseases are closely linked to the immune system …

Perivascular inflammation is a prominent pathologic feature in most animal models of
pulmonary hypertension (PH) as well as in pulmonary arterial hypertension (PAH) patients …

This review summarizes an expanding body of knowledge indicating that failure to resolve
inflammation and altered immune processes underlie the development of pulmonary arterial …

Macrophages play a key role in defending against foreign pathogens, healing wounds, and
regulating tissue homeostasis. Driving this versatility is their phenotypic plasticity, which …

Numerous molecular abnormalities have been described in pulmonary arterial hypertension
(PAH), complicating the translation of candidate therapies to patients because, typically, 1 …

Pulmonary arterial hypertension (PAH) describes a group of conditions with a common
hemodynamic phenotype of increased pulmonary artery pressure, driven by progressive …

Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein that improves
cardiopulmonary function in patients with pulmonary arterial hypertension (PAH) by …

Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary dysfunctional disease,
characterized by progressive vascular remodeling. Inflammation is an increasingly …